诺乙雄龙是一种合成代谢类固醇. 在1965年FDA批准药物上市销售商品名Nilevar，在荷尔蒙不足、严重烧伤患者的治疗、严重创伤后、再生障碍性贫血等方面作为雄激素合法使用。现在只有澳大利亚，法国和瑞士市场上有销售。

注意：此处包括了那些只有微弱男性化效应（或抗男性化（如氧雄龙））的蛋白同化甾类（因为它们合成代谢效应也是通过激活雄激素受体而是显得）。

Note: 21-Hydroxylase inhibitors may also affect androgen levels as they prevent metabolism of androgen steroid precursors.

Norethandrolone (INN, BAN) (brand names Nilevar, Pronabol), also known as 17α-ethyl-19-nortestosterone, is an anabolic steroid. It was synthesized at G. D. Searle & Company in 1953 and was originally studied as a progestin, along with norethisterone and noretynodrel, but was ultimately not marketed as such. In 1955, it was re-examined for testosterone-like activity and was found to have similar anabolic activity to testosterone but only one-sixteenth the androgenic potency. The drug was introduced in the United States as an anabolic steroid in 1965 under the trade name Nilevar but was withdrawn from the market in the 1980s due to concerns of cholestatic jaundice. Norethandrolone is now only marketed in Australia, France, and Switzerland, and as with all 17α-alkylated oral steroids, long-term use in high doses may result in elevated liver enzymes and consequently cirrhosis. It is used in the treatment of muscle wasting, patients with severe burns, after severe trauma, and for certain forms of aplastic anemia.